AVATR CE Mark medical device:: study planning and preparation  (Option 1)

The project supports the management of long-term conditions related to Cardiovascular Diseases (CVD), which are the leading cause of death globally, representing 31% of all global deaths. People with cardiovascular disease or who are at high cardiovascular risk (due to the presence of one or more risk factors such as hypertension, diabetes, hyperlipidaemia or already established disease) need early detection and management using counselling and medicines, as appropriate.

This proposal directly addresses the challenge by creating a service that helps improve methods and systems within a local health ecosystem based on the needs of the citizen at home and in the community, whereby pharmacist-led services in GP practices and community pharmacies are fully engaged as a key healthcare resource. The project aims to prevent CVD and improve clinical outcomes, helping to reduce costs and demand on NHS hospitals and GP practices. In doing so, the project will increase patient access to innovative technologies.

The project is led by Inavya Ventures Ltd, a UK-based SME that has created the CE marked medical device 'AVATR' to help patients with chronic diseases, with current deployment at the National Heart Centre in Singapore and Einstein Hospital in Sao Paulo. Deployed on a smartphone, AVATR provides management and remote monitoring of data from medical-grade wearables and also contextual information from other sources, such as diet, exercise, GPS location, local air quality. Take-up of AVATR requires testing the performance of AVATR in order to quantify clinical and operational improvements, and cost-saving to NHS.

The project is supported by Firza Primary Care (unfunded), which has access to over 600,000 NHS patients and delivers pharmacist-led clinical support services to 90 GP Practices throughout England; and GreenLife Pharma (unfunded), which provides technical, commercial and NHS clinical support services to 50 pharmacies to improve income growth and productivity while reducing expenditure. 42 of these pharmacies are owned by its parent company, Imaan Healthcare.During this four month project we aim to develop a detailed feasible plan to generate evidence directly from a local healthcare ecosystem of the clinical and cost-saving benefits of AVATR to the NHS. This evidence will enable AVATR to engage with the NHS and other markets, delivering commercial benefits to the partners, clinical improvements and cost saving to the NHS, and improved service to patients and citizens.